Scientists identify new form of dementia

pharmafile | May 1, 2019 | News story | Research and Development AD, Alzheimer's, dementia, late, neuroscience 

A team of scientists from Britain and the United States have described a new form of dementia, according to a study published in the journal Brain.

The researchers are calling the disorder ‘limbic-predominant age-related TDP-43 encephalopathy’ or LATE for short.

While similar to Alzheimer’s disease, the disorder, which is generally found in the ‘oldest-old’, is separate from Alzheimer’s.

Nevertheless, the researchers believe that many cases of LATE may have been mistaken for Alzheimer’s disease in the past.

While LATE and Alzheimer’s are similar in regards to the effects they have on patient’s cognitive functions, they affect patient’s brains in different ways.

While the brains of Alzheimer’s patients are marked by the build-up of TAU and amyloid-β plaques, the researchers found that patients with LATE have an accumulation of the protein TDP-43 in their brains.

However patients with LATE neuropathological change (LATE-NC) may also have build-ups of TAU and amyloid-β plaques. LATE is often comorbid with Alzheimer’s disease, the study says.

The researchers believe that LATE-NC is present in more than 20% of individuals older than 80. This figure could be as high as 50% the study says.

“LATE probably responds to different treatments than AD, which might help explain why so many past Alzheimer’s drugs have failed in clinical trials,” Dr Peter Nelson of the Sanders-Brown Center on Aging at the University of Kentucky, said.

“Now that the scientific community is on the same page about LATE, further research into the ‘how’ and ‘why’ can help us develop disease-specific drugs that target the right patients.”

Louis Goss

Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …


Cognixion receives FDA Breakthrough Device Designation for assisted communication device

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced …

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing …

Latest content